Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, which will see it add microparticle capabilities to its portfolio of drug delivery technologies. Halozyme will purchase fellow subcutaneous drug delivery specialist Elektrofi for $750m upfront, along with with three separate $50m milestone payments. Elektrofi will receive these payments if three products, which are currently undisclosed, are approved following the takeover. Elektrofi’s platform, called Hyercon, cr ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s revised price target depends on the biotechnology company’s projected 2025 revenues being 8.5 times higher. The firm also reported that Mer ...